Immunic, Inc.

NASDAQ:IMUX

Biotechnology

Healthcare
$7.52 -0.28%

-$0.04 today

Market cap
$102.61M
Beta
1.39
P/E (TTM)
-4.1
EPS (TTM)
-$3.46
52W Low $5.06High $15.77

Volume 0.17M

Average 0.27M

IMUX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Immunic, Inc.NASDAQ: IMUX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $25.63M rose 19.0% year over year, ahead of the +3.9% change in trailing-twelve-month research & development. Sequentially, it rose 34.4% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +19.0% holds above the trailing-twelve-month pace of +3.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.63M+34.4% QoQ
Last fiscal yearDec 2025
$81.98M+2.4% YoY
LTMMar 2026
$86.08M+3.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.0%——
1 year+2.4%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
81.98M USD
Year-over-year change
+2.4%
4-year CAGR
+7.6%

Research & Development vs competitors

How IMUX compares with its peers on the latest reported figures

  • IMUX's LTM Mar 2026 research & development of $86.08M is the 4th highest of the 9 companies compared; the peer median is $63.68M.
  • Its year-over-year change of +3.9% is the 3rd highest of 9, against a peer median of -8.6%.
  • Over three fiscal years its annual growth of +4.8% compares with a peer median of +17.8%.
IMUX Competitors Peer median
Research & Development for IMUX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$200.25M +133.0%+35.5%78.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
ACETAdicet Bio, Inc.LTM Mar 2026$93.8M -4.5%+11.6%—
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M +8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
CBUSCibus, Inc.LTM Mar 2026$41.12M -18.1%+56.4%959.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
Peer median (excluding IMUX) $63.68M-8.6%+17.8%959.3%

Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development61.12M71.26M83.22M80.05M81.98M
Selling, General & Admin13.3M15.26M16.01M18.01M21.25M
Operating Expenses91.67M119.49M99.22M98.05M103.23M
Depreciation & Amortization85K77K111K134K168K
EBITDA(92.86M)(86.44M)(93.5M)(100.37M)(97M)
EBITDA Margin—————
Operating Income(91.67M)(119.49M)(99.22M)(98.05M)(103.23M)
Operating Margin—————
Interest Income66K1.04M3.08M3.39M1.04M
Interest Expense01.04M000
Other Income / Expenses(1.28M)(919K)5.61M(2.46M)6.06M
Income Before Tax(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Net Margin—————
EPS (Basic)(39.20)(37.80)(21.10)(10.00)(6.24)
EPS (Diluted)(39.20)(37.80)(21.10)(10.00)(6.24)
Weighted Avg Shares2.37M3.18M4.43M10.02M15.57M
Weighted Avg Shares (Diluted)2.37M3.18M4.43M10.02M15.57M

Immunic, Inc.

NASDAQ:IMUX

Intrinsic Alpha fair value

Locked

Current Price

$7.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.